9th Annual MSK Symposium on Lymphoma — On Demand

This annual symposium provides a comprehensive overview of the latest advancements in the evolving field of lymphoma. The 9th edition of the program, originally recorded live from April 25–26, 2025, brought together leading national and international experts to present cutting-edge discoveries in lymphoma biology, state-of-the-art diagnostic techniques, and innovative treatment strategies. The program highlights the clinical management of common lymphoma subtypes while also exploring groundbreaking drug developments, advances in lymphoma biology and pathology, and how these discoveries are being translated into meaningful improvements in patient care. To view the full agenda and list of presentations, please refer to the brochure from the live symposium.

Session Topics

• Current Challenges in the Management of Follicular Lymphoma

• Advances in Therapeutic Strategies for Mantle Cell Lymphoma

• Hodgkin Lymphoma

• The Dark Side of B-Cells

• Improving Outcomes for Patients with T-Cell Lymphoma

• Aggressive B-Cell Lymphoma: Addressing Remaining Gaps on the Path to a Definitive Cure

• CAR T-Cell Therapies in Large B-Cell Lymphoma: Who, When, and How?

Keynote Presentations

• Chris Flowers, MD, MPH (MD Anderson Cancer Center): Epidemiology and Outcomes in Lymphoma

• Margaret Shipp, MD (Dana-Farber Cancer Institute): Biology of Hodgkin Lymphoma

• David Maloney, MD, PhD (Fred Hutchinson Cancer Research Center): Lessons and Challenges

Special Breakout Session: Empowering APPs and Nurses

Designed specifically for interdisciplinary care teams, this breakout sessions emphasizes their pivotal role in advancing lymphoma treatment.

Target Audience

This program is designed for internists, oncologists, hematologists, medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in the diagnosis, treatment, and research of lymphoma.

1. Describe recent advances in lymphoma classification
2. Discuss first line treatment options in most frequent lymphoma entities
3. Describe new agents mode of actions, efficacy, side effects
4. Discuss options and recommendations for patients in the relapse refractory setting
5. Provide adequate information to help shared decision with patients regarding their treatment

To enroll, please click the "Register" tab at the top of the page. Once registered, all materials—including instructions for claiming credit—will be available under the "Course Content" tab. On-demand access and the ability to claim credit will remain available through December 31, 2025.

On Demand Access Fees

• Physicians (MDs, PhDs, and DOs): $450

• Advanced Practice Providers: $200

• Nurses and Other Healthcare Providers: $150

• Residents and Fellows: $100

• MSK Employees: Complimentary

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

This Memorial Sloan Kettering Continuing Medical Education on demand program is non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 12.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 12.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and

• 12.50 Lifelong Learning (CME) credits in the American Board of Pathology’s (ABPath) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.

Recorded/Review Date: April 25-26, 2025 | Original Release Date: May 31, 2025 | Termination Date: December 31, 2025

MSK Symposium Director

Gilles Salles, MD, PhD
Chief, Lymphoma Service

MSK Planning Committee

Ahmet Dogan, MD, PhD
Chief, Hematopathology Service

Lauren Drosick, PA-C
Advanced Practice Provider

Kojo S.J. Elenitoba-Johnson, MD
Chair, Department of Pathology and Laboratory Medicine 

Sean E. Healton, MD, PhD
Hematology/Oncology Fellow

Steven Horwitz, MD
Attending Physician, Lymphoma Service

Andrew Intlekofer, MD, PhD
Assistant Member, Human Oncology & Pathogenesis Program

Alison J. Moskowitz, MD
Associate Attending Physician, Lymphoma  Service

Ariela Noy, MD
Member, Lymphoma Service

Hans-Guido Wendel, MD
Member/Professor, Cancer Biology and Genetics Program

Joachim Yahalom, MD, FACR, FASTRO
Attending Radiation Oncologist, External Beam Radiotherapy Service

Andrew D. Zelenetz, MD, PhD 
Medical Director, Quality Informatics;
Attending Physician, Lymphoma Service 

Invited Faculty 

Christopher R. Flowers, MD, MS
Division Head, Division of Cancer Medicine;
Chair, Professor, Department of Lymphoma/Myeloma
MD Anderson Cancer Center 
Houston, TX

Georg Lenz, MD
Professor of Medicine;
Director Department of Hematology, Oncology and Pneumology
University Hospital Münster
Münster Germany

Brian K. Link, MD
Professor Emeritus of Internal Medicine - Hematology, Oncology, and Blood & Marrow Transplantation 
University of Iowa College of Medicine
Iowa City, IA

Kami J. Maddocks, MD
Professor in the College of Medicine 
The Ohio State University
Columbus, OH

David G. Maloney, MD, PhD
Fred Hutchinson Cancer Research Center 
University of Washington
Seattle, WA

Coraline Mlynarczyk, PhD
Assistant Professor of Medicine (Hematology) 
Yale School of Medicine
New Haven, CT

Laura Pasqualucci, MD
Professor of Pathology and Cell Biology 
Columbia University
New York, NY 

Barbara Pro, MD
Professor of Medicine;
Director of Lymphoma Program
Herbert Irving Comprehensive Cancer Center
New York, NY 

Sandrine Roulland, PharmD, PhD
Inserm Research Director
Centre d’Immunologie de Marseille Luminy
Marseille, France

Sarah Rutherford, MD
Associate Professor of Clinical Medicine
Weill Cornell Medicine
New York, NY

Clémentine Sarkozy, MD, PhD
Institut Curie
Paris, France

Margaret A. Shipp, MD
Chief, Division of Hematologic Neoplasia, Dana Farber Cancer Institute;
Professor of Medicine, Harvard Medical School 
Boston, MA

MSK Faculty 

Ashley Ames, MSN, RN, FNP-BC
Advanced Practice Provider

Annalisa Benz, BSN, RN, OCN
Clinical Nurse III

Alexander P. Boardman, MD
Assistant Attending Physician, Lymphoma Service

Theresa Davey, PA
Advanced Practice Provider

Zachary Epstein-Peterson, MD
Attending Physician, Lymphoma Service 

Lorenzo Falchi, MD
Assistant Attending Physician, Lymphoma Service

Jennifer Gorelov, AGNP-BC, MSN
Advanced Practice Provider

Dana Guerra, BSN, RN
Clinical Nurse II

Paul A. Hamlin, MD
Attending Physician, Lymphoma Service

Brandon Imber, MD, MA
Assistant Attending Radiation Oncologist, External Beam Radiotherapy Service

Anita Kumar, MD
Associate Attending Physician, Lymphoma Service 

Efrat Luttwak, MD, MPH
Assistant Attending Physician, Lymphoma Service 

Ivan Maillard, MD, PhD
Attending Physician, Leukemia Service;
Head of the Division of Hematologic Malignancies

Joanna Mi, MSN, AGPCNP-BC, AOCNP® 
Advanced Practice Provider

M. Lia Palomba, MD
Member, Lymphoma Service and Cellular Therapeutics Service

Shenon Sethi, MBBS
Assistant Attending Pathologist, Hematopathology Service

Gunjan L. Shah, MD
Assistant Attending Physician, Bone Marrow Transplant and See all Cellular Therapy Services

Marcel Smith, MSN, FNP, MSPharm, AOCNP
Advanced Practice Provider

Emily Spevack, BSN, RN, OCN®
Clinical Nurse III

Raphael Steiner, MD
Associate Attending Physician, Lymphoma Service 

Robert Stuver, MD
Assistant Attending Physician, Lymphoma Service 

Pallawi Torka, MD
Assistant Attending Physician, Lymphoma Service 

Jasmine M. Zain, MD
Lymphoma Service

Ting Zhou, MD
Assistant Attending Pathologist, Hematopathology Service

Relevant faculty disclosures as of the recording dates, April 25–26, 2025.

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.